Founded with a mission to advance groundbreaking therapies, Vesigen Therapeutics is a biotechnology company focused on overcoming delivery barriers to unlock novel treatments. The company leverages its patented ARMMs (ARRDC1 Mediated Microvesicles) technology to efficiently deliver gene editors, proteins, and RNA to intracellular targets. This non-viral platform aims to expand the universe of druggable targets, offering innovative solutions for various medical conditions.
Vesigen Therapeutics has attracted notable investors and industry experts, contributing to its rapid growth and development. The company's ARMMs technology has garnered significant attention for its potential to revolutionize therapeutic delivery. By enabling more efficient and targeted delivery mechanisms, Vesigen is poised to make a substantial impact on the biotechnology landscape, driving forward the possibilities for novel and effective treatments.
